neuroscience

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect…

2 weeks ago

NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207

NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, March 23, 2026 /PRNewswire/ -- The New York…

2 months ago

HKUST President Prof. Nancy IP Engages in Global Dialogues at Davos 2026 on Neuroscience, University Leadership, and the Future of Research

HONG KONG, Jan. 26, 2026 /PRNewswire/ -- Prof. Nancy IP, President of The Hong Kong University of Science and Technology (HKUST),…

4 months ago

New data reinforces Ipsens commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement…

5 months ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP July 18, 2025…

11 months ago